Evidence map›Paper›PMID 37392367›Full record

ArticleAnnals of hematology2023

Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).

Mihee Kim, Je-Jung Lee, Chang-Ki Min, Ji Yun Lee, Jae-Cheol Jo, Sung-Soo Yoon, Sung-Nam Lim, Young Rok Do, Kihyun Kim, Jae Hoon Lee and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 1 country.

Mihee KimChonnam National University Hwasun Hospital, Chonnam National University Medical School, Hawsun, Jeollanam-do, Republic of Korea.
Je-Jung LeeChonnam National University Hwasun Hospital, Chonnam National University Medical School, Hawsun, Jeollanam-do, Republic of Korea.
Chang-Ki MinSeoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Ji Yun LeeSeoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Jae-Cheol JoUlsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
Sung-Soo YoonSeoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Sung-Nam LimInje University College of Medicine, Haeundae Paik Hospital, Busan, Republic of Korea.
Young Rok DoKeimyung University, Dongsan Medical Center, Daegu, Republic of Korea.
Kihyun KimSungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Jae Hoon LeeGachon University Gil Medical Center, Incheon, Republic of Korea.
Kwai Han YooGachon University Gil Medical Center, Incheon, Republic of Korea.
Sung Hwa BaeDaegu Catholic University Hospital, Daegu, Korea.
Jun Ho YiChung-ang University Hospital, Seoul, Republic of Korea.
Jongheon JungNational Cancer Center, Goyang, Republic of Korea.
Hyeon-Seok EomNational Cancer Center, Goyang, Republic of Korea. hseom@ncc.re.kr.
Sung-Hoon JungChonnam National University Hwasun Hospital, Chonnam National University Medical School, Hawsun, Jeollanam-do, Republic of Korea. shglory@hanmail.net.
Chonnam National University Hwasun Hospital · KRGachon University Gil Medical Center · KRNational Cancer Center · KRCatholic University of Korea · KRChung-Ang University Hospital · KRDaegu Catholic University Medical Center · KRInje University Haeundae Paik Hospital · KRKeimyung University Dongsan Medical Center · KRSeoul National University Bundang Hospital · KRSeoul National University Hospital · KRSungkyunkwan University · KRUniversity of Ulsan · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the development of effective agents for multiple myeloma (MM), the management of patients with high-risk MM (HRMM) is challenging. High-dose treatment followed by autologous stem cell transplantation (ASCT) is regarded as upfront treatment for transplant-eligible patients with HRMM. In the present study, we retrospectively investigated the efficacies of two conditioning regimens for upfront ASCT in newly diagnosed patients with MM and high-risk features: high-dose melphalan (HDMEL; 200 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsBusulfanHumansMelphalanRetrospective StudiesStem Cell TransplantationTransplantation, AutologousTransplantation ConditioningBusulfanMelphalanBusulfanHigh-risk cytogeneticsMelphalanMultiple myelomaStem cell transplantation

Identifiers

PMID37392367
OpenAlexW4382797367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.